References
- Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in Type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 24, 1614–1619 (2001).
- SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325, 293–302 (1991).
- Saad MF, Knowler WC, Pettitt DJ, Nelson R, Charles MA, Bennett PH. A two-step model for development of non-insulin dependent diabetes. Am. J. Med. 90, 229–235 (1990).
- Lillioja S, Mott D, Spraul M et al. Insulin resistance as precursor of non-insulin-dependent diabetes mellitus. Prospective studies on Pima Indians. N. Engl. J. Med. 329, 1988–1992 (1993).
- Yki-Jarvinen H. Pathogenesis of non-insulin-dependent diabetes mellitus. Lancet 343, 94–95 (1994).
- Randle PJ, Hales CN, Garland PB, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin insensitivity and the metabolic disturbance of diabetes mellitus. Lancet 785–789 (1994).
- Randle PJ, Priestman DA, Mistry S, Halsall A. Mechanisms modifying glucose oxidation in diabetes mellitus. Diabetologia 37(Suppl. 2), S155–S161 (1994).
- Paolisso G, De Riu S, Marrazzo G, Verza M, Varricchio M, D’Onofrio F. Insulin resistance and hyperinsulinemia in patients with chronic congestive heart failure. Metabolism 40, 972–977 (1991).
- Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 35): prospective observational study. Br. Med. J. 321, 405–412 (2000).
- Zannad F, Briancon S, Julliere Y et al. and the EPICAL investigators. Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL study. J. Am. Coll. Cardiol. 33, 734–742 (1999).
- Bell DSH. Diabetic cardiomyopathy: a unique entity or a complication of coronary artery disease? Diabetes Care 18, 708–714 (1995).
- Factor SM, Minase T, Sonnenblick EH. Clinical and morphological features of human hypertensive-diabetic cardio-myopathy. Am. Heart J. 99, 446–458 (1980).
- Kelley DE, Morkan M, Simoneau JA, Manadrino L. Interaction between glucose and free fatty acid metabolism in human skeletal msucle. J. Clin. Invest. 92, 91–98 (1993).
- Cohn JN, Levine TB, Olivari MT et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N. Engl. J. Med. 311, 819–823 (1984).
- Marangou AG, Alford FP, Ward G et al. Hormonal effects of norepinephrine on acute glucose disposal in humans: a minimal model analysis. Metabolism 37, 885–891 (1988).
- Paolisso G, Gambardella A, Marrazzo G et al. Metabolic and cardiovascular benefits deriving from β-adrenergic blockade in chronic congestive heart failure. Am. Heart J. 123, 103–110 (1992).
- Svedberg J, Bjontorp J, Smith U, Lonnroth P. Effect of free fatty acids on insulin receptor binding and tyrosine kinase actvity in hepatocytes from lean and obese rats. Diabetes 41, 294–298 (1992).
- Paolisso G, Tataranni A, Foley J, Howard BV, Ravussin E. A high concentration of fasting plasma free fatty acids is a risk factor for the development of non-insulin dependent diabetes mellitus. Diabetologia 38, 1213–1217 (1995).